Denali Therapeutics Inc. (DNLI) vs Enliven Therapeutics, Inc. (ELVN)

A side-by-side comparison of Denali Therapeutics Inc. and Enliven Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — DNLI vs ELVN

growth of $100 · dividends reinvested · last 7y
DNLI +10.7% (+1.5%/yr)ELVN -24.2% (-3.9%/yr)DNLI compounded faster over this window
0100200300400500Start $100202120222023202420252026$111$76
DNLI ELVN

DNLI vs ELVN: by the numbers

  • •ELVN is the larger company ($3.25B vs $3.16B market cap).
  • •Both run net losses; ELVN's is the smaller (0.00% vs -14191.20% net margin).

Metrics side by side

Valuation

MetricDNLIELVN
P/S ratio876.78N/A
P/B ratio3.783.63

Profitability

MetricDNLIELVN
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin-14191.20%0.00%
ROE-61.24%-11.83%
ROIC-50.82%-13.88%

Growth (annualized)

MetricDNLIELVN
Revenue CAGR (5Y)20.68%N/A
Total return CAGR (5Y)-16.91%24.57%

Frequently asked

How have DNLI and ELVN total returns compared?
Over the past 5 years, DNLI delivered -16.91% and ELVN delivered 24.57% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.